GenEditBio is focused on advancing gene editing technologies to create a precision gene editing platform aimed at developing safe and effective programmable gene therapy products. The company employs multiple technology platforms to address the challenges associated with in vivo gene editing therapy. Their approach includes the mining and optimization of novel Cas nucleases, which enhances their capabilities in gene editing by providing a diverse range of potent and precise nucleases. Additionally, GenEditBio has developed a new editing system that allows for versatile sequence manipulations, enabling the correction of various genetic alterations associated with human diseases.

The company is also innovating in gene delivery methods, creating novel tools that facilitate the effective and transient delivery of gene editing reagents. These advancements aim to minimize off-target effects and improve the specificity of targeting desired tissues. By leveraging these technologies, GenEditBio aspires to develop "one-and-done" therapies that offer durable effects, particularly in the treatment of Mendelian genetic diseases, viral infections, and cancer, thereby revolutionizing therapeutic approaches in healthcare.

Hong Kong

GenEditBio is a biotech startup company aiming to provide potentially curative gene editing-based solutions for genetic diseases that have no cures or lack simple treatments today. GenEditBio is formed by a group of scientists and entrepreneurs who are passionate in gene editing-based approaches to treat diseases rooted in altered DNA bases or chromosomal structures. At GenEditBio, we develop leading-edge technologies for safe and precise gene editing, towards clinically viable gene therapies.

GenEditBio

Company Details